Classys

클래시스 · 214150

Health Care Medical Devices · KOSDAQ

Large-cap

Market cap US$2B (₩2.8T)

Overview

Classys makes medical devices used in aesthetic clinics to tighten skin and reshape facial contours without surgery, using energy-based technologies such as focused ultrasound, radiofrequency, microneedle radiofrequency, and laser.

Its devices and the consumables required to operate them are supplied to clinics, hospitals, and distributors across more than eighty countries worldwide. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company's portfolio spans its Ultraformer, Volnewmer, Everesse, Quadessy, and reepot device lines, covering the main categories of energy-based aesthetic treatment.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$244.1M
▲ +38.6% YoY
Operating profit · FY2025
US$123.6M
▲ +39.3% YoY
Net income · FY2025
US$95.6M
▲ +35.3% YoY

Revenue

  • FY2023US$130.5M
  • FY2024US$176M
  • FY2025US$244.1M

Operating profit

  • FY2023US$64.9M
  • FY2024US$88.7M
  • FY2025US$123.6M

Net income

  • FY2023US$53.8M
  • FY2024US$70.7M
  • FY2025US$95.6M

Key ratios (FY2025)

ROE
23.9%
Debt/Eq
27.7%
Op. margin
50.6%
Net margin
39.2%
Rev. YoY
▲ +38.6%

Why it matters

Alongside device sales, consumables, single-use items required each time a machine is operated, form a distinct and recurring revenue category as the installed base of devices grows.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.